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Overline: Myopathy 
 
One Sentence Summary 
Augmenting the heat shock response with Arimoclomol ameliorates pathology in cellular and 
animal models of Inclusion Body Myositis (IBM) and is safe and well tolerated in IBM patients.   
 
Accessible Summary:  
Targeting protein dyshomeostasis in sporadic IBM: sIBM is a debilitating adult myopathy 
without treatment. Although both inflammation and protein dyshomeostasis are implicated in 
sIBM pathogenesis, previous trials have only targeted the inflammatory component, and all 
have failed. Here, we tested the effects of targeting protein dyshomeostasis, using 
Arimoclomol, a co-inducer of the heat shock response. In rat myoblast models, Arimoclomol 
reduced key pathological features of IBM. In vivo, in mutant valosin-containing protein (VCP) 
mice, which develop an inclusion body myopathy, treatment with Arimoclomol ameliorated 
disease pathology and improved muscle function. A safety and tolerability trial of Arimoclomol 
in sIBM patients showed that Arimoclomol was safe and well tolerated. 
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Abstract 
Sporadic inclusion body myositis (sIBM) is the commonest severe myopathy in patients over 
age 50. Previous therapeutic trials have targeted the inflammatory features of sIBM, but all 
have failed. Since protein dyshomeostasis may also play a role in sIBM, we tested the effects 
of targeting this feature of the disease. Using rat myoblast cultures, we found that up-regulation 
of the heat shock response with Arimoclomol reduced key pathological markers of sIBM in 
vitro. Furthermore, in mutant valosin-containing protein VCP mice, which develop an 
inclusion body myopathy (IBM), treatment with Arimoclomol ameliorated disease pathology 
and improved muscle function. We therefore evaluated the safety and tolerability of 
Arimoclomol in an investigator-lead, randomised, double-blind, placebo-controlled, proof-of-
concept patient trial and gathered exploratory efficacy data which showed that Arimoclomol 
was safe and well tolerated.  Although Arimoclomol improved some IBM-like pathology in 
vitro and in vivo in the mutant VCP mouse, we did not see statistically significant evidence of 
efficacy in this proof of concept patient trial.  
 
Introduction 
Sporadic inclusion body myositis (sIBM) is the commonest idiopathic inflammatory myopathy 
(IIM) occurring in patients over 50 years of age (1-7), but no treatment is available. The 
prevalence of sIBM differs between different populations and ranges between 1 and 71 
individuals per million (8-13). sIBM is distinguished from other IIMs by early asymmetric 
finger flexor and knee extensor weakness leading to loss of hand function and propensity to 
fall, and resistance to immunosuppressive therapy. However, any skeletal muscle may be 
affected including oesophageal and pharyngeal muscles. Late-stage disease is characterized by 
significant morbidity, including motor disability, swallowing failure and poor quality of life. 
Death in IBM is related to malnutrition, cachexia, aspiration, and respiratory failure (1-7). 
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Although the aetiology of sIBM remains uncertain, the varied pathological findings 
observed in patient muscles have driven a number of hypotheses, including viral infection, 
accumulation of toxic proteins, autoimmune attack, myonuclear degeneration, endoplasmic 
reticulum (ER) stress and impairment of autophagy and proteasomal function (14-18). Muscle 
biopsies from sIBM patients typically show several pathological features broadly described as 
either inflammatory or degenerative. Inflammatory features include endomysial infiltration by 
mononuclear cells, which surround and invade non-necrotic muscle fibres and overexpression 
of major histocompatibility complex class I (MHC-I), which is not constitutively expressed by 
skeletal muscle. The degenerative features of sIBM include the formation of rimmed vacuoles 
and inclusion bodies containing a range of proteins including β-amyloid precursor protein (β-
APP), heat shock proteins (HSPs), phosphorylated tau (p-Tau), p62 and the cytoplasmic 
mislocalisation of RNA-binding proteins including transactive response DNA binding protein 
43 (TDP-43), heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) and hnRNPA2B1 (19-
22).  
 
Despite lack of any experimental evidence, protein accumulation could theoretically 
play a role in triggering inflammation in IBM muscle. For example, amyloid oligomers can 
induce key components of sIBM pathology, at least in vitro, so that β-APP overexpression and 
consequent accumulation impairs innervation by co-cultured neurons (23), causes 
mitochondrial dysfunction (24), and in vivo, results in calcium dyshomeostasis (25). 
Conversely, inflammation may induce the onset of degenerative features through exposure to 
inflammatory cytokines and increased nitric oxide production (26). In muscle biopsies of sIBM 
patients, expression of APP mRNA correlates with inflammation and expression of mRNAs of 
chemokines and IFN-γ. Furthermore, unlike muscles of inflammatory myopathies, in sIBM 
muscles, inflammatory mediators co-localize with -amyloid deposits within myofibres. In 
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vitro, exposure of human myotubes to IL-1 causes upregulation of APP with subsequent 
aggregation of -amyloid. These findings suggest there is a link between the production of pro-
inflammatory mediators and -amyloid-associated degeneration in sIBM muscle (27). 
Previous clinical trials in sIBM have only tested agents directed at the inflammatory 
component of pathology and all were ineffective (3, 4, 28-31). Whether the degenerative aspect 
of IBM is primary to the pathogenesis or not, it very likely plays a role in the deleterious effects 
in muscle, and may be a potential therapeutic target. Protein homeostasis (proteostasis) is 
essential for normal cellular functions (32) and in conditions of cellular stress, proteins can 
become unfolded or misfolded, leading to their aberrant aggregation (33). Protein misfolding 
is normally controlled by endogenous chaperone proteins (34) that prevent aberrant protein-
protein interactions and promote correct protein folding. Heat shock proteins are a family of 
ubiquitously expressed protein chaperones, which are up-regulated following stress-induced 
activation of the heat shock response, an endogenous cytoprotective mechanism. Since the heat 
shock response declines with advanced age (35), upregulation of the heat shock response in 
disorders in which there is evidence of protein mishandling, such as sIBM, may be of 
therapeutic value.  
Arimoclomol is a pharmacological agent that co-induces the heat shock response (36) 
by prolonging the activation of Heat Shock Factor-1 (HSF-1) (32), the main transcription factor 
that controls heat shock protein expression, thus augmenting heat shock protein levels (36-39). 
Importantly, Arimoclomol only acts on cells under stress in which HSF-1 is already activated, 
and does not induce the heat shock response in unstressed cells (40) thereby avoiding the side 
effects associated with widespread non-targeted heat shock response activation. Indeed, 
previous examination of the effects of Arimoclomol in mice has shown that treatment with 
Arimoclomol has no detectable effect on non-stressed cells, and there was no increase in heat 
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shock protein expression in any tissue studied (including spleen, heart, brain, spinal cord, nerve 
and muscle).  
In this study, we took a 3-step translational approach to test whether heat shock 
response augmentation may be a potential therapy for sIBM. We first established robust in vitro 
models representing the degenerative and inflammatory components of sIBM. Primary rodent 
myotube cultures were induced to overexpress human -amyloid precursor protein (β-APP) by 
transfection of the wild-type human gene, or cultures were exposed to the inflammatory 
cytokines interleukin 1β (IL1β) and tumor necrosis factor  (TNFα). In these models, muscle 
cells developed several key IBM-like pathological features, which were used as outcome 
measures to examine the therapeutic potential of Arimoclomol in IBM. Having established the 
beneficial effects of Arimoclomol in vitro, we next tested its ability to ameliorate sIBM-like 
pathology in mice overexpressing mutant valosin-containing protein (VCP; p97 in mouse). 
These transgenic mice model the degenerative disorder Multisystem Proteinopathy (MSP), 
which has a phenotypic spectrum that includes Inclusion Body Myopathy, Paget’s Disease of 
the bone, and frontotemporal dementia (41). Although these mice are a model of the genetic 
rather than sporadic form of IBM, they do develop progressive muscle weakness and 
pathological hallmarks of inclusion body myopathy. In addition, we also undertook a 
randomized, double-blind, placebo-controlled (RDBPC), proof-of-concept trial of 
Arimoclomol verses placebo for the treatment of sIBM in human patients. The aim of this trial 
was to evaluate the safety and tolerability of Arimoclomol and to gather exploratory efficacy 
data. 
 
 
Results  
Arimoclomol improves sIBM-like pathology in myoblast cultures 
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We first established accurate in vitro models of sIBM–like pathology in which primary rat 
myoblast cultures were either transfected with β-APP or exposed to inflammatory cytokines. 
For both cell culture models, we first undertook a series of titrating experiments to determine 
the optimal conditions; the effects of different DNA and lipofectamine ratios or different 
cytokine concentrations on β-APP and Aβ40 and Aβ42 expression was examined, at different 
stages in vitro. 
 
 
Transfection of primary rat myocytes with full-length human β-APP increased the 
expression of β-APP and its toxic cleavage product amyloid beta-42 (Aβ-42), and led to the 
formation of cytoplasmic inclusion bodies, a hallmark of sIBM, containing β-APP, ubiquitin 
and TDP-43, amongst other proteins (Fig.1A-C; Fig.S1A-E). Treatment with Arimoclomol 
post-transfection, significantly reduced the formation of cytoplasmic inclusions (p<0.01; n=3; 
Fig.1A-C). Additionally, β-APP overexpression increased the expression of MHC-I, a 
characteristic feature of sIBM muscle and the proapoptotic protein caspase-3 (Fig.S1F). 
Exposure of cultured rat myocytes to IL1β and TNFα was also associated with elevated 
expression of β-APP and Aβ-42, although in the absence of inclusion body formation. 
Increased MHC-I expression was also reproduced in the cytokine-exposed cultures (Fig.S1G). 
Similar results were obtained with IFN-γ. 
Overexpression of β-APP or exposure to inflammatory mediators resulted in 
cytoplasmic mislocalisation of the C-terminus of TDP-43 from the nucleus (Fig.1D-G), which 
is a key pathological feature of sIBM patient muscle. This mislocalisation was almost 
completely prevented by treatment with Arimoclomol (Fig.1D-G). Thus, whereas only 
1.4±0.6% of rat myocytes showed mislocalised TDP-43 in control cultures, overexpression of 
β-APP induced TDP-43 mislocalisation in 52.2±5.3% of myocytes, which was reduced to only 
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2.4±0.53% following treatment with Arimoclomol for 24 hours post-transfection (P<0.001; 
n=3).  
Treatment with inflammatory mediators also induced TDP-43 mislocalisation in rat 
myocytes, which was also reduced by Arimoclomol treatment, from 47.4±2.8% to 24.8±2.0% 
in myocyte cultures exposed to IL1β (P<0.05) and 59.9±9.0% to 29.8±2.1% in TNFα-exposed 
cultures (P<0.05). In addition, exposure to inflammatory cytokines also increased the overall 
level of TDP-43 expression, and this was also reduced by treatment with Arimoclomol 
(Fig.1H). The N-terminus of TDP-43 remained in its nuclear location under all conditions 
studied (Fig.S1H).  
Although the extent of TDP-43 mis-localisation induced by β-APP overexpression and 
exposure to inflammatory mediators was similar, Arimoclomol was more effective in 
preventing TDP-43 mis-localisation in the β-APP overexpression model. This difference most 
likely reflects the underlying cause of TDP-mislocalisation in the two models, where stress 
induced by protein misfolding is the key pathological trigger in β-APP overexpressing cells. 
Arimoclomol directly reduces levels of misfolded proteins and cell stress by upregulating the 
heat shock response. The mode of action of Arimoclomol in the inflammatory models is less 
direct, and may involve a general reduction in cell stress and consequently NF-κB activation, 
as shown in Fig. 1I-K. 
β-APP overexpression also activated the NF-κB cascade, most likely as part of a non-
specific stress response, as shown by nuclear translocation of the NF-κB subunit p65, observed 
in 43.1±6.2% of myocytes in β-APP transfected cultures compared to 8.8±1.2% in control 
cultures (P<0.01; Fig.1I,K). Treatment with Arimoclomol reduced this to 23.6±4.2% (P<0.05). 
Unsurprisingly, exposure to inflammatory cytokines also activated the NF-κB cascade, from 
4.6±1.3% and 9.1±1.4% in control cultures to 88.1±6.3% and 38.9±2.9% (P<0.001) in IL1β-
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treated and TNFα-treated cultures, respectively (Fig.1J,K). Arimoclomol reduced this effect to 
41.2± 6.8% (P<0.05) and 24.3± 3.1% (P<0.05), respectively.  
 
Arimoclomol augments HSP70 expression and improves cell survival  
Overexpression of β-APP and exposure to inflammatory mediators resulted in a significant 
increase in HSP70 expression, which increased by 3.7 and 2.3 fold of control following β-APP 
overexpression and treatment with IL1β, respectively (p<0.05, n=3). Arimoclomol increased 
HSP70 expression further, by 2.4 and 2.1 fold in β-APP and IL1β treated cultures, respectively 
(Fig.2A-C). There was no difference in HSP70 levels in untreated controls and empty vector 
treated cultures (Fig. S1 I). β-APP overexpression and exposure to inflammatory mediators 
also resulted in significant cell death, which was reduced by treatment with Arimoclomol 
(p<0.05; n=3; Fig.2D,E). 
 
Arimoclomol attenuates ER Stress and protein mishandling  
β-APP overexpression and exposure to inflammatory mediators increased endoplasmic 
reticulum (ER) stress in cultured rat myocytes, as determined by measurement of intracellular 
calcium ions, where reduced cytosolic [Ca2+] was indicative of ER stress. In β-APP over-
expressing cells exposed to the ER stressor, thapsigargin, cytosolic [Ca2+] was significantly 
lower than in controls (p<0.05; n=3; Fig.3A). β-APP overexpression also induced upregulation 
of expression of the ER stress mediator CHOP (Fig.3B). This β-APP-induced disruption in ER 
calcium ion handling was prevented by treatment with Arimoclomol, where cytosolic [Ca2+] 
was significantly increased to the levels observed in control cultures (p<0.05, n=3; Fig.3A), 
accompanied by a decrease in CHOP expression (Fig.3B).  
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Exposure to the inflammatory cytokines IL1β and TNFα also resulted in a significant reduction 
in cytosolic [Ca2+] (Fig.3A) and an increase in the expression of CHOP (Fig.3B). Treatment 
with Arimoclomol restored cytosolic [Ca2+] to control levels and reduced the expression of 
CHOP (p<0.05; n=3; Fig.3A, B).  
Aberrant expression of the shuttle protein p62 (Sequestosome 1) was observed in β-
APP overexpressing cells (Fig.3C). This protein targets misfolded proteins for degradation and 
was observed in cytoplasmic aggregates in cultured rat myocytes, suggesting altered protein 
handling. Assessment of proteasomal function demonstrated a significant decrease in 
proteasomal activity following β-APP overexpression (p<0.05; n=3), however, this was not 
improved by treatment with Arimoclomol (Fig.3E). Autophagic degradation was assessed by 
examination of the autophagosome marker LC3 II, which increased by 1.28-fold in β-APP 
overexpressing cells compared to controls. However, this was reduced to 0.74-fold the 
expression level of controls in Arimoclomol-treated cultures, indicating a reduction in 
autophagic degradation, possibly due to a reduction in mis-folded proteins (p<0.05; n=3; 
Fig.3D, F). 
 
Arimoclomol ameliorates IBM-like pathology in mutant VCP mice 
Arimoclomol has clear beneficial effects in cellular models of sIBM. We therefore next tested 
the efficacy of Arimoclomol in vivo in mutant VCP mice. These mice model Multisystem 
Proteinopathy (MSP) and develop characteristic hallmarks of inclusion body myopathy (IBM). 
Mutant VCP mice were treated with Arimoclomol from 4 to 14 months of age. By 14 months, 
there was a significant decrease in muscle force in mutant VCP mice (p<0.0001; n=10), as 
assessed by longitudinal analysis of grip strength as well as acute in vivo physiological 
assessment of isometric muscle force (Fig. 4A-C). The loss of muscle force observed at 14 
months was prevented by treatment with Arimoclomol. Grip strength was significantly greater 
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in treated mutant VCP mice than untreated mice (p=0.0175; n=10; Fig.4A-C). There was also 
an improvement in the toe-spreading reflex observed in Arimoclomol-treated mutant VCP mice 
(Fig.S2A,B). However, Arimoclomol had no effect on the abnormal increase in body weight 
observed in mutant VCP mice (Fig.S2C). Histopathological analysis of hind-limb muscles of 
mutant VCP mice confirmed the presence of significant IBM-like pathology including 
myofibre atrophy, increased endomysial connective tissue, the presence of degenerating fibres 
and vacuoles as well as hypertrophic fibres (Fig 4D). All of these pathological findings were 
reduced in Arimoclomol-treated mutant VCP mice (Fig.4D-I; Movie S1). In addition, mutant 
VCP mouse muscles showed evidence of inflammatory cell infiltration as well as upregulation 
of major histocompatibility complex I (MHC-I) and the phosphorylated form of the NFκB 
substrate, IκBα. (Fig. 4E-G). There was no evidence of inflammatory infiltrates in 
Arimoclomol-treated mutant VCP mouse muscles and levels of MHC-I and IκBα were reduced 
(Fig.4E-G). In particular, treatment with Arimoclomol dramatically improved mitochondrial 
morphology and reduced sarcoplasmic reticulum swelling and vacuole number in mutant VCP 
mouse muscle fibres compared to controls (Fig.4H; Movie S2-S4). Furthermore, the 
macrophage infiltration observed in mutant VCP mouse muscle was also reduced in 
Arimoclomol-treated mice (Fig. S2D-F). Arimoclomol-treated mutant VCP mouse muscles 
also showed an decrease in the muscle fibre diameter compared to untreated mutant mouse 
muscle (p<0.0001; n=3; Fig.4I). These beneficial effects of Arimoclomol were accompanied 
by an increase in HSP70 expression in mutant VCP mouse muscles (Fig.4J), a decrease in the 
expression of ubiquitin (Fig.5A-C) and a reduction in cytoplasmic mis-localisation of TDP-43 
(p=0.01; n=3; Fig.5D-F).  
 
 
Clinical trial of safety and tolerability of Arimoclomol for the treatment of sIBM 
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We next undertook a randomized, double-blind, placebo-controlled (RDBPC) proof-of-
concept trial of Arimoclomol versus placebo for the treatment of sIBM. The primary aim of 
the trial was to evaluate the safety and tolerability of Arimoclomol, but exploratory efficacy 
data were also gathered. Sixteen sIBM patients were randomized to receive Arimoclomol and 
eight to receive placebo. The duration of the treatment period was 4 months, and the follow-up 
continued for a further 8 months after treatment ceased, with an overall trial duration of 12 
months. At 4 months (end of the treatment phase) all sIBM patients were still participating in 
the trial. At 8 months, two patients had discontinued the study (due to travel difficulties), but 
one of these patients returned for the final assessment at 12 months (Fig. S3). Baseline clinical 
and demographic characteristics were similar between groups (Table S1).  
There were no significant differences between treatment groups regarding the rate, type 
and severity of adverse events (Table S2). There were 8 adverse events in the placebo group 
and 14 in the Arimoclomol group, the most common being gastrointestinal (see Table S2 for 
details). In the Arimoclomol group, one serious adverse event was reported as a result of 
persistent high blood pressure requiring overnight hospitalization in a patient with known 
poorly-controlled hypertension, in whom the first trial muscle biopsy was identified as a 
stressful event. Blood pressure normalized after adjustment of the patient´s anti-hypertensive 
medication and kept within the normal range throughout the remainder of the trial. 
Hypertensive episodes were also observed in two placebo patients, under similar 
circumstances, although these cases did not require hospitalization. Two cases of hyponatremia 
and one case of high thyroxine levels were observed in the Arimoclomol group, however these 
were transient, asymptomatic and did not require treatment. The episode of hematuria in the 
Arimoclomol group was also limited and did not require treatment. All infections resolved with 
standard treatments, with or without antibiotics, and did not require hospitalization. Ocular 
toxicity and arrhythmia were not observed in any study subjects. 
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Clinical trial secondary outcomes 
Overall, there was no statistically significant difference in the secondary outcome measures 
favouring Arimoclomol. However, there were trends in favour of Arimoclomol, but these will 
require a formal large-scale patient trial powered for efficacy to be assessed further. Physical 
function and muscle strength decline rates over time were numerically higher in the placebo 
group compared to the Arimoclomol group (Fig. 6; Table S3). At 8 months, there was a trend 
favoring the Arimoclomol group, with a P-value of 0.055 for change in the IBM Functional 
Rating Scale (IBMFRS) score (-0.68±1.58 vs. -2.50±3.31), 0.147 for change in the average 
Manual Muscle Testing (MMT) score (-0.12±0.22 vs. -0.26±0.27), and 0.064 for change in the 
right grip Maximum Isometric Voluntary Contraction Testing (MVICT) score (1.26±2.63 vs. 
-0.54±1.86). No differences were seen for changes in the other MVICT scores, changes in dual-
energy X-ray absorptiometry (DEXA) fat free mass percentage, or changes in myosin-adjusted 
HSP70 expression in muscle (Table S3).  
 
Discussion  
Here, we examined the effects of targeting the heat shock response in sIBM. In sIBM patients, 
Arimoclomol was found to be safe and well tolerated, with a trend of a slower decline in muscle 
strength and physical function compared with placebo control sIBM patients, although the 
trend was not significant. Although we did not observe statistically significant clinical efficacy 
or significant morphological changes in the repeat muscle biopsies taken from Arimoclomol-
treated patients, studies both in cellular models in vitro and in an in vivo mouse model which 
recapitulates many features of sIBM in muscle showed that the pathological and functional 
deficits associated with sIBM were ameliorated by Arimoclomol in these model systems.  
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In vitro, both β-APP overexpression and exposure to inflammatory cytokines induced 
degenerative sIBM-like pathology in rat myocytes, including an increase in the formation of 
ubiquitinated inclusion bodies. Treatment with Arimoclomol reduced inclusion body 
formation, indicating an improvement in protein handling. This was most likely due to 
upregulation of the heat shock response, in particular enhanced HSP70 expression. Both 
models also recapitulated the increase in mis-localised TDP-43 observed in sIBM patient 
myofibres. TDP-43 is cleaved by caspase-3 (42), allowing the C-terminus to leave the nucleus, 
thus linking its translocation to increased cell stress. Arimoclomol also reduced TDP-43 
mislocalisation and TDP-43 expression in cultures exposed to inflammatory mediators, 
suggesting that the drug reduced levels of cell stress. Indeed, both β-APP overexpression and 
inflammatory mediators induced cell death, which was reduced by Arimoclomol.  
 Nuclear translocation of the NF-κB subunit p65, which was observed following 
exposure to IL1β and TNFα, was examined as an indication of NF-κB activation. β-APP 
overexpression also activated NF-κB as has been observed in cellular models of Alzheimer’s 
disease in which Aβ42 peptide activates the inflammatory cascade (43), most likely as part of 
a non-specific stress response. Arimoclomol had an inhibitory effect on NF-κB activation in 
both the β-APP and the inflammatory cell models, which likely reflects upregulation of the 
heat shock response and  downregulation of the NF-κB signaling cascade by heat shock 
proteins (44).  
Arimoclomol also decreased the disruption in ER calcium ion homeostasis induced in 
both the β-APP and inflammatory cell models of sIBM and consequently reduced the ER stress 
response, a key mechanism triggered by aberrantly folded proteins. This was reflected by 
restoration of cytosolic calcium ion concentrations. Indeed, in TNFα-treated rat myotube 
cultures, the reduction in cytosolic calcium ion concentration was prevented by Arimoclomol, 
as was the expression of the ER stress mediator CHOP. This protective effect of Arimoclomol 
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may reflect, at least in part, the chaperone activity due to augmented expression of HSP70, 
which serves to improve the efficiency of handling and degradation of misfolded proteins.  
Examination of the two major protein degradation pathways in the cell culture models 
revealed disruption in both proteasome function and increased autophagy. However, 
Arimoclomol had no effect on proteasome function, although formation of mature 
autophagosomes was reduced, suggesting a reduced misfolded protein load in the lysosomal 
pathway. 
In vivo, treatment of mutant VCP mice with Arimoclomol improved the pathological 
features and functional deficits characteristic of the inclusion body myopathy associated with 
multisystem proteinopathy (MSP). Thus, in Arimoclomol-treated mutant VCP mice we 
observed an increase in muscle strength and a reduction in key pathological hallmarks of IBM, 
including decreased ubiquitin expression, a reduction in cytoplasmic mis-localisation of TDP-
43, and a dramatic improvement in mitochondrial morphology accompanied by an increase in 
heat shock protein expression.  
These findings provide evidence for the beneficial effects of Arimoclomol in 
experimental models of sIBM. This supports clinical assessment of the effects of Arimoclomol 
in sIBM patients. The primary endpoint of our randomised, double-blind, placebo-controlled, 
proof-of-concept trial in sIBM patients was met, with results showing that Arimoclomol was 
both safe and well tolerated by sIBM patients. Regarding the secondary endpoints (efficacy 
measures), there were no statistically significant differences between the treatment groups. 
However, this was not surprising since this first experimental study of a compound targeting 
the heat shock response in sIBM had several limitations. These included the small sample size, 
which had been advised by our ethics committees and the FDA because Arimoclomol had 
never been given to sIBM patients before and this study was intended as a proof-of-
concept/safety study that was not powered for efficacy. The short duration of treatment (only 
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4 months) was also mandated by regulatory agencies. In a slowly progressing disease like 
sIBM, longer treatment periods are likely to be required in order to be able to detect changes 
in efficacy outcome measures. Whether Arimoclomol can ameliorate sIBM pathology will only 
be determined by performing adequately powered clinical trials of longer duration. A 12 month 
study powered for efficacy that will enroll 150 IBM patients has now been approved and fully 
funded and enrollment will commence in late 2016. .  
Finally, regarding the measurement of muscle HSP70 expression in sIBM patients, this 
read-out also had several limitations, namely the fact that muscle HSP70 expression is 
extremely sensitive to multiple factors, including disease stage, physical activity, age and 
gender (45-47) and the fact that muscles on opposite sides of the body were biopsied at baseline 
and post-treatment. 
Arimoclomol has previously been shown to be safe in both animal models and humans 
(36, 39, 48) and has been indicated to be of potential therapeutic benefit in several neurological 
disorders including diabetic peripheral neuropathy and retinopathy (49). Arimoclomol has also 
been found to be beneficial in animal models of neurodegeneration, including models of acute 
injury-induced neuronal death (37) and has been shown to have therapeutic value in mouse 
models of motor neuron disease, including ALS (36, 50) and Kennedy’s Disease (51). 
Arimoclomol has been through seven phase I clinical trials in healthy volunteers to assess its 
safety, tolerability and pharmacokinetic properties as well as a small-scale phase II trial in ALS 
patients (48). A phase IIa dose-ranging trial in ALS has shown Arimoclomol to be safe and 
well tolerated up to 100 mg three times daily (52) and a phase II/III randomised, double-blind, 
placebo-controlled trial is currently underway in familial SOD1-ALS patients 
(NCT00706147). 
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Our results show that Arimoclomol is safe and well tolerated in sIBM patients, and 
ameliorates key degenerative and inflammatory features of IBM pathology in experimental 
cellular and animal models. Together, these findings support further investigation of 
Arimoclomol for the treatment of sIBM.  
 
Materials and Methods 
Study Design 
In this study, we took a 3-step translational approach to test whether augmentation of the heat 
shock response may be a potential therapy for sIBM, by examining the effects of Arimoclomol 
in rat muscle cells in vitro, in a preclinical study in mutant VCP mice, and in sIBM patients in 
a safety and tolerability trial. In vitro, the effects of Arimoclomol were examined in rat primary 
muscle cultures overexpressing β-APP or treated with inflammatory cytokines, by assessing 
the effects on IBM-relevant histopathological characteristics. All experiments were repeated in 
at least 3 independent cultures. In the preclinical efficacy study, mutant VCP mice were 
randomized to Arimoclomol or vehicle treatment arms and the effects on muscle force and 
histopathological characteristics were set as the study endpoints. The experimenter was blind 
to genotype and treatment group throughout. In sIBM patients, we undertook a randomized, 
double-blind, placebo-controlled, proof-of-concept trial of Arimoclomol versus placebo, to 
evaluate the safety and tolerability of Arimoclomol and to gather exploratory efficacy data, by 
testing muscle strength and HSP70 expression. This trial was an exploratory study conducted 
without prior knowledge of effect size of Arimoclomol in sIBM. The sample size was chosen 
based on feasibility. Randomization was performed centrally for both study sites.  
 In vitro model of IBM  
Primary muscle cultures were used as an in vitro model of IBM by extracting satellite cells that 
lie under the basal lamina of myofibres.  Muscle cells were induced to model either the 
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degenerative features of sIBM, by over-expression of β-APP, or the inflammatory 
characteristics, by treatment with inflammatory mediators (see Supplementary Methods for 
details of muscle culture preparation and treatment).  
 
In these in vitro models of sIBM, the following features of sIBM pathology were examined 
and the effects of treatment with 10 µM Arimoclomol investigated: i) inclusion body 
formation; ii) heat shock protein expression; iii) cytoplasmic translocation of TDP-43; iv) cell 
survival; v) NFκB activation; vi) ER Stress (for details see Supplementary Material). 
Breeding and maintenance of mutant VCP mice 
All experimental procedures were carried out under licence from the UK Home Office 
(Scientific Procedures Act 1986), and following approval by the UCL Institute of Neurology’s 
Animal Welfare and Ethical Review Board. Mice overexpressing the wildtype or mutant 
(A232E) human VCP gene under the CMV-enhanced chicken -actin promoter [see Custer et 
al. (40)] were bred and maintained at UCL Institute of Neurology. Transgenic females carrying 
the wildtype or mutant gene were mated with wild-type C57BL/6J males to generate transgenic 
and non-transgenic littermates. Only male offspring were used in this study to prevent gender 
differences. The mice were genotyped by PCR amplification of ear notches and analysed using 
agarose gel electrophoresis and visualized using GelRed™ stain (Sigma-Aldrich). All mice 
used in this study were housed in a controlled temperature and humidity environment with a 
12-hour light/dark cycle and had access to drinking water and food ad libitum. 
Treatment of mutant VCP mice with Arimoclomol 
 
Following genotyping, male mice were randomly assigned to a treatment or vehicle arm of the 
study. From 4 months of age to the time of examination at 14 months, mutant VCP mice were 
treated with 120 mg/kg/day Arimoclomol dissolved in drinking water (n=10) or water alone 
(vehicle; n=10). The body weight of all mice was recorded fortnightly. Arimoclomol was 
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obtained from Orphazyme ApS. All experiments were undertaken blinded to genotype and 
treatment. 
Longitudinal assessment of grip strength and body weight 
Grip strength was assessed fortnightly in all mice from 4-14 months of age, using a 
BiosebTM force gauge according to the manufacturer's instructions. An average of four 
maximum readings was obtained. Body mass was recorded at the same time as grip strength. 
The ratio of Grip strength:body mass was determined for individual animals and were pooled 
by each genotype. 
In vivo analysis of isometric muscle force 
The mice were prepared for in vivo assessment of muscle function (see Kieran et al. 
(2004)(35)). Briefly, mice were deeply anaesthetized (inhalation of 1.5–2.0% isoflurane in 
oxygen delivered through a Fortec vaporizer (Vet Tech Solutions Ltd)). The distal tendons of 
the tibialis anterior (TA) and extensor digitorum longus (EDL) muscles in both hindlimbs were 
dissected free and attached to isometric force transducers (Dynamometer UFI Devices). The 
sciatic nerve was exposed, sectioned and all branches cut except for the deep peroneal nerve 
that innervates the TA and EDL muscles. Muscle length was adjusted for maximum twitch 
tension. Isometric contractions were elicited by stimulating the nerve to the muscles using 
square-wave pulses of 0.02 ms duration at supra-maximal intensity using silver wire electrodes. 
Contractions were elicited by trains of stimuli at frequencies of 40, 80 and 100 Hz for 450 ms 
and the maximum twitch and tetanic tension was measured using force transducers connected 
to a Picoscope 3423 oscilloscope (Pico Technology) and subsequently analysed using 
Picoscope Software v5.16.2 (PicoTechnology). Muscle histology, immunohistochemistry, 
western blot and electron microscopy protocols are described in the Supplementary material. 
Clinical trial design and patient population 
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In this investigator-initiated, double-blind, placebo-controlled study, 24 patients meeting the 
Griggs diagnostic criteria for definite or probable sIBM (53, 54) were randomised to 
Arimoclomol (100 mg) or placebo (2:1 ratio), three times a day, over 4 months (treatment 
phase). This restricted 4-month treatment period, mandated by the US Food and Drug 
Administration (FDA), was followed by an 8-month blinded assessment phase. The study was 
conducted from August 2008 to May 2012, at two Centres in two countries (12 
patients/Centre): University of Kansas Medical Centre (KUMC), Kansas, USA, and Medical 
Research Council (MRC) Centre for Neuromuscular Diseases, London, UK. Detailed inclusion 
and exclusion criteria can be found in the Supplementary Methods. 
Randomization was performed centrally for both study sites at KUMC. This was done 
by a General Clinical Research Centre statistician, who sent the randomization codes, created 
using a random number generator table, to the respective research pharmacies. All personnel 
involved in the conduct of the trial were blind to the identity of the treatment assignments, 
except for the unblinded statistician and the pharmacist at each site who labelled the study 
medication using codes provided by the unblinded statistician. The appearance of the placebo 
was identical to that of Arimoclomol. 
The study was conducted according to the ethical principles of the Declaration of 
Helsinki and approved by the Independent Ethics Committee or Institutional Review Board for 
each Centre. Informed consent was obtained from each patient before randomization. The study 
was registered with ClinicalTrials.gov (NCT00769860) and with International Standard 
Randomised Controlled Trial Number Register (ISRCTN80057573). 
Clinical trial: Primary outcomes 
The safety and tolerability of Arimoclomol compared to placebo was the primary outcome of 
the trial. Participants were seen for assessment of adverse events at every study visit. 
Unscheduled visits to evaluate potential adverse events could occur at any time. All serious 
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adverse events were reported to the sponsor and regulatory authorities according to standard 
operating procedures. The trial was monitored by an Independent Safety Monitoring 
Committee.  
During the first 4 months (treatment phase), all participants completed a study 
medication diary. Pill bottles were brought to each visit for a count by a research team member 
to check on whether participants were taking the study medication in the appropriate dosages. 
At screening and months 1, 2, 3, 4 and 12, the study participants had full safety laboratory 
analyses done which included: full blood count with differential, prothrombin time, activated 
partial thromboplastin time, urea, creatinine and electrolytes, glucose, phosphate and calcium, 
alanine transaminase, aspartate transaminase, total bilirubin, albumin, full urine analysis and 
24-hour urine protein content and creatinine clearance. At months 0.5, 1.5, 2.5, and 3.5, 
participants had partial safety laboratory analyses done including: serum creatinine, urea, 
electrolytes, glucose, phosphate, calcium and a full urine analysis. An electrocardiogram was 
performed at screening and months 1 and 3. An ophthalmic examination was performed at 
screening and month 10. The electrocardiogram and ophthalmic examination were introduced 
as safety measures following results from an animal model study which raised concerns of 
potentially accelerated cataract formation and apparent risk of sudden, unexplained death with 
Arimoclomol at very high doses and with Arimoclomol used in conjunction with riluzole 
(CytRx Corporation. Arimoclomol Investigator´s Brochure version 7.0, September 2010). 
Clinical trial: Secondary outcomes 
Physical function was measured using the IBM functional rating scale (IBMFRS) that is 
intended only for patients with sIBM. It includes 10 measures (swallowing, handwriting, 
cutting food and handling utensils, fine motor tasks, dressing, hygiene, turning in bed and 
adjusting covers, changing position from sitting to standing, walking, and climbing stairs), 
graded on a Likert scale from 0 (being unable to perform) to 4 (normal). The sum of the 10 
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items gives a value between 0 and 40, with a higher score representing less functional 
limitation. The IBMFRS is a sensitive and reliable tool for assessing activities of daily living 
in patients with sIBM and is quickly administered (see Supplementary Methods) (7, 30, 55-
57). 
Muscle strength was assessed by manual muscle testing (MMT) and by maximum 
voluntary isometric contraction testing (MVICT) using the Quantitative Muscle Assessment 
(QMA) system designed by Computer Source, Atlanta, Georgia, USA (30, 57) (see 
Supplementary Methods). Each muscle was tested twice and the maximum force generated by 
the patient from the two trials was recorded for each muscle group. The total summed score of 
strength in kilograms was computed for each patient. MVICT has been shown to be reliable 
and valid in several neuromuscular disorders, including sIBM (30, 57, 58). Body composition 
was obtained using a standard dual-energy X-ray absorptiometry (DEXA) whole body scan to 
assess total body fat-free mass. DEXA has been used to measure lean body mass in previous 
neuromuscular disease studies, including sIBM (30, 57). Patient muscle HSP70 expression was 
determined as described in the Supplementary Methods. 
Statistical methods 
In the preclinical cellular model and mutant VCP mouse model, analysis of normally 
distributed results was performed using an unpaired t-test or, for comparison of greater than 
two groups, a one-way ANOVA. Otherwise, the non-parametric Mann-Whitney U-test was 
used.  
Data management and statistical analysis were performed by General Clinical Research 
Centre (GCRC) informatics staff and a GCRC statistician. Data was entered blindly to a GCRC 
password-protected electronic database and analyses were performed after database lock. 
Descriptive statistics were used to summarize subject disposition and adverse events by 
treatment group. In order to reduce measurement error, baselines scores were computed by 
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calculating the average of visit 1 (screening visit) and visit 2 (baseline visit), which had to be 
less than 21 days apart. Continuous variables were compared between treatment groups using 
the Mann-Whitney U test. Categorical variables were compared between treatment groups 
using Chi-square or Fisher´s exact test, as appropriate. Treatment groups were compared at 
baseline as well as regarding changes in the several outcome measures at 4 months (IBMFRS, 
MMT, MVICT, DEXA and HSP70 content), 8 months (IBMFRS, MMT and MVICT) and 12 
months (IBMFRS, MMT, MVICT and DEXA).  
Statistical analyses were performed using STATA v10 and in all analyses statistical 
significance was set at the two-sided 5% level. Error bars represent standard error of the mean 
unless otherwise stated. 
 
Supplementary Materials 
Materials and Methods 
Fig. S1. Overexpression of β-APP and exposure to inflammatory mediators induces sIBM-like 
pathology in cultured myocytes. 
Fig. S2. Mutant VCP mice show further signs of pathology. 
Fig. S3. Consort diagram of the patients participating in the clinical trial. 
Table S1. Baseline characteristics of the study population. 
Table S2. Summary of all adverse events over the course of 1 year. 
Table S3. Mean changes (± standard deviation) in secondary outcome measures throughout 
the study period. 
Movie S1. Low-magnification serial blockface scanning electron microscopy of Arimoclomol-
treated and untreated mutant VCP mouse muscle. 
Movie S2. High-magnification serial blockface scanning electron microscopy of wildtype VCP 
mouse muscle. 
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Movie S3. High-magnification serial blockface scanning electron microscopy of untreated 
mutant VCP mouse muscle. 
Movie S4. High-magnification serial blockface scanning electron microscopy of Arimoclomol-
treated mutant VCP mouse muscle. 
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Figures  
Fig. 1.  
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Fig. 1. β-APP overexpression or exposure to inflammatory mediators induces sIBM-like 
pathology in cultured rat myocytes that is abrogated by Arimoclomol. 
Shown is formation of cytoplasmic inclusion bodies (white arrows) in rat myocytes transfected 
with full-length human β-APP immunoreactive for (A) β-APP and ubiquitin and (B) TDP-43 
and ubiquitin. (C) The number of myocytes containing ubiquitinated inclusion bodies as a 
percentage of the total number of myocytes present (n=3; p<0.05; one-way ANOVA). (D) 
Expression of TDP-43 (green) following empty vector (EV) or β-APP transfection and 
Arimoclomol treatment, and (E) the number of myocytes with cytoplasmic mislocalisation of 
TDP-43 (n=3, p<0.001; unpaired t-test). (F) TDP-43 expression (green) following exposure to 
inflammatory mediators and Arimoclomol, and (G) quantification of TDP-43 mislocalisation 
in cytokine-treated cultures (n=3, p<0.05; unpaired t-test). (H) Western blot analysis of TDP-
43 expression in rat myocyte cultures exposed to cytokines in the presence and absence of 
Arimoclomol. Images show the expression of NF-κB subunit p65 (green) in (I) β-APP 
transfected cultures (DAPI labelled nuclei in blue), and (J) cultures exposed to cytokines in the 
presence and absence of Arimoclomol. (K) The number of rat myocytes with nuclear NF-κB 
subunit p65 as a percentage of the total number of myocytes present (n=3, p<0.05; one-way 
ANOVA). Error bars = S.E.M; scale bars: A, B =10 µm, D, I and J =20 µm. * indicates 
statistical significance.  
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Fig. 2.  
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Fig. 2. Arimoclomol augments HSP70 expression and improves survival of cultured rat 
myocytes. 
(A) HSP70 expression (red) in cultured rat myocytes following empty vector (EV) transfection 
(left hand panel), β-APP overexpression (middle panel), or β-APP overexpression plus 
treatment with Arimoclomol (right hand panel). (B) HSP70 expression (red) in cultured rat 
myocytes that were untreated (control; left hand panel), or after exposure to IL-1β alone 
(middle panel) or IL-1β plus Arimoclomol (right hand panel). (C) Western blot analysis of 
HSP70 expression in rat myocyte cultures exposed to inflammatory mediators or after β-APP 
overexpression in the presence or absence of Arimoclomol. (D) Cytotoxicity in β-APP 
overexpressing rat myocyte cultures as a percentage of that in control cultures (n=3, p<0.02; 
one-way ANOVA), as assessed by a lactate dehydrogenase (LDH) assay. (E) Cytotoxicity 
following exposure to inflammatory mediators in the presence or absence of Arimoclomol 
(n=3, p<0.05; one-way ANOVA), as assessed by an MTT (3-(4, 5-dimethylthiazolyl-2)-2,5-
diphenyltetrazolium bromide) assay. Error bars= S.E.M.; Scale bars=10 µm. * indicates 
statistical significance. 
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Fig. 3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Disruption of protein homeostasis in rat myocyte cultures is prevented by 
Arimoclomol 
 (A) The cytosolic calcium ion response induced by the ER stressor thapsigargin (an indicator 
of ER stress) in β-APP overexpressing rat myocyte cultures and in cell cultures exposed to 
inflammatory mediators (n=3, p<0.05; one-way ANOVA). (B) Expression of the ER stress 
mediator CHOP determined by Western blot analysis in rat myocyte cultures overexpressing 
β-APP or exposed to inflammatory mediators, in the presence or absence of Arimoclomol. (C) 
The images show the presence of a cytoplasmic aggregate immunoreactive for p62 (red; white 
arrow) in a desmin-positive rat myocyte following β-APP transfection. (D) The images show 
the expression of the autophagic protein LC3-II (red; white arrow) in β-APP transfected 
desmin-positive rat myocytes after Arimoclomol treatment. The white arrow indicates punctate 
LC3-II staining of autophagosomes. (E) The chymotrypsin-like proteasome activity assessed 
48 hours after β-APP transfection in the presence or absence of Arimoclomol (n=3, p<0.05; 
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one-way ANOVA). (F) The expression of the autophagosome marker LC3 II  in β-APP 
transfected rat myocytes with or without Arimoclomol (n=3, p<0.05; one-way ANOVA). EV, 
empty vector. Error bars=S.E.M; Scale bars=10 µm. * indicates statistical significance. 
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Fig. 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 44 
Fig. 4. Arimoclomol treatment improves muscle strength, muscle contractile 
characteristics and IBM-like pathology in mutant VCP mice 
(A) The change in grip strength in wildtype VCP (WT-VCP), mutant VCP (mVCP) and 
Arimoclomol-treated mutant VCP (mVCP+Ari) mice between 4 and 14 months (n=10; 
p<0.0001; unpaired t-test). (B) Typical traces of muscle twitch and maximum tetanic force of 
extensor digitorum longus (EDL) muscles in untreated and Arimoclomol-treated mutant VCP 
mice. (C) Mean maximum force of extensor digitorum longus muscles of WT-VCP, mutant 
VCP and Arimoclomol-treated mutant VCP mice (n=10; p<0.04; one-way ANOVA). (D) H&E 
staining of tibialis anterior (TA) muscles of mice in each experimental group (white arrow, 
atrophied fibre; black arrowheads, hypertrophic fibres). (E) H&E staining showing clear 
inflammatory cell infiltration in mutant VCP tibialis anterior  muscle. Western blots show (F) 
MHC-1 and (G) phospho-IκBα expression in tibialis anterior  muscles of mice in each 
experimental group. (H) Transmission electron microscopy of tibialis anterior  muscles of mice 
in each experimental group. (I) Muscle fibre diameter in tibialis anterior muscles from 
untreated and Arimoclomol-treated mutant VCP mice compared to WT-VCP mice (n=3; 
p<0.0001; one-way ANOVA). (J) Western blot analysis of HSP70 expression in tibialis 
anterior muscles from mice in each experimental group. Bar chart shows mean relative optical 
density (n=3; p=0.01; unpaired t-test). Error bars = S.E.M, Scale bars: D, E =50 µm; F=2µm. 
* indicates statistical significance.  
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Fig. 5.  
 
 
 
 
 
 
 
 
 
Fig. 5. Arimoclomol abrogates IBM-like pathology in mutant VCP mouse muscle. 
Cross sections of tibialis anterior muscles from wildtype VCP (WT-VCP), mutant VCP 
(mVCP) and Arimoclomol-treated mutant VCP (mVCP+Ari) mice, immunostained for 
ubiquitin (red; A-C) and TDP-43 (green; D-F); nuclei stained with DAPI (blue). Scale bar = 
50 µm; inserts = 25 µm. 
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Fig. 6. 
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Fig. 6. Clinical trial secondary outcomes (efficacy measures) 
The change from baseline to endpoint on 3 different clinical scales assessed at 4, 8 and 12 
months (M) (mean ± S.E.M) in sIBM patients treated with Arimoclomol for 4 months. (A) 
IBMFRS score, (B) MMT average score, and (C) right hand grip MVICT score. The IBMFRS 
is a disease-specific functional questionnaire for patients with sIBM and measures physical 
function/disability. MMT is a measure of muscle strength scored by the physician based on the 
clinical assessment. MVICT is a measure of muscle strength performed using a quantitative 
muscle assessment system that uses an adjustable cuff to attach the patient's arm or leg to an 
inelastic strap that is connected to a force transducer. Error bars = S.E.M. No statistically 
significant clinical efficacy measures were observed.  
